



Treatment.

Recombinant protein for the treatment of viral diseases.

A research group from the Public Health System of Andalusia (SSPA) and the University of Malaga have developed a recombinant protein for the prevention, control, treatment and / or relief of a viral disease.

Oficina de **TRANSFERENCIA DE TECNOLOGÍA**
Sistema Sanitario Público de Andalucía



Description

The medical improvements produced in viral therapy diseases are of less magnitude than those that have been achieved for the treatment of bacterial infections. **The development of highly effective wide spectrum antiviral agents is a primary objective shared by the fields of virology and pharmacology.**

Viruses are intracellular parasites that use the metabolic machinery of the infected host cell. Therefore, the development of antivirals presents a series of difficulties associated with this obligate parasitic character. It is difficult to achieve adequate antiviral activity without affecting the host cell metabolism and without causing negative effects in other non-infected cells of the organism.

Current strategies to control viral infectivity are based on the identification of agents capable of intervening in the essential steps of viral infection. Another strategy would be aimed at the modulation of the cellular defense system.

IFN β exerts its biological activity through interaction with the **IFNAR** surface receptor formed by two subunits, IFNAR1 and IFNAR2. The IFNAR2 subunit of the receptor undergoes a processing that gives rise to three different isoforms, of which only IFNAR2c has been suggested to have a neutralizing capacity for the binding of IFN β to the IFNAR2 receptor. In this way he could exercise modulating functions according to the concentration he is in.

This research group has verified the antiviral effect of a recombinant protein. They suggest its use in the preparation of an antiviral treatment.



Advantages

It comprises a new strategy in prevention and / or treatment of diseases caused by viruses.



Industrial Property

This technology is protected by national and European patent.



Aims

The research group is looking for partnership and/or license agreement.



Classification

Area: Treatment.

Pathology: Infectious diseases.



http://www.ibima.eu/grupo_investigacion/neuroinmunologia-y-neuroinflamacion/